• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Heartbeam Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    6/24/26 5:28:27 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care
    Get the next $BEAT alert in real time by email
    false 0001779372 0001779372 2026-06-18 2026-06-18 0001779372 us-gaap:CommonStockMember 2026-06-18 2026-06-18 0001779372 us-gaap:WarrantMember 2026-06-18 2026-06-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 18, 2026

     

    HEARTBEAM, INC.

    (Exact name of Registrant as specified in its charter)

     

    Delaware   001-41060   47-4881450

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    2118 Walsh Avenue, Suite 210

    Santa Clara, CA 95050

    (Address of principal executive offices, including zip code)

     

    (408) 899-4443

    (Registrant’s telephone number, including area code)

     

    Check the appropriate box below if the 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

     

    ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock   BEAT   NASDAQ
    Warrant   BEATW   NASDAQ

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Robert P. Eno Departure

     

    On June 18, 2026, Heartbeam, Inc. (the “Company”) and Mr. Eno mutually agreed to his departure as the Company’s Chief Executive Officer, as a member of the Company’s Board of Directors (the “Board”), and as the Company’s principal executive officer, effective as of June 30, 2026, in connection with a strategic reorganization within the Company. Mr. Eno’s decision to depart is not the result of any dispute or disagreement with the Company on any matter relating to the Company’s operations, policies or practices. In connection with Mr. Eno’s departure, it is expected that he and the Company will enter into a consulting agreement whereby Mr. Eno is expected to provide support services to the Company following June 30, 2026, in an advisory capacity. Any payment of the severance amounts pursuant to the terms of Mr. Eno’s Employment Agreement dated as of January 17, 2023 (the “Employment Agreement”) is subject to Mr. Eno’s execution of a release of claims satisfactory to the Company. The description of Mr. Eno’s Employment Agreement is qualified in its entirety by reference to the full text of the Employment Agreement, which is included as Exhibit 10.2 to the Current Report on Form 8-K filed by the Company on January 18, 2023.

     

    Until a new Chief Executive Officer is identified, the Company will strategically align its operations around focused implementation teams led by Branislav Vajdic, Ph.D., Founder and President, and Rich Ferrari, Executive Chairman of the Board. Dr. Vajdic, will also serve as the Company’s principal executive officer, effective July 1, 2026.

     

    Biographical information and information regarding related party transactions with respect to Dr. Vajdic and Mr. Ferrari is contained in Part III, Items 10 and 13 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, which Items are incorporated by reference herein.

     

    Mark Strome Resignation

     

    On June 18, 2026, Mark Strome notified the Company of his resignation from the Board and all committees thereof, effective immediately. Mr. Strome's resignation was not due to any dispute or disagreement with the Company on any matter relating to the Company's operations, policies, or practices.

     

    Item 8.01 Other Events.

     

    On June 24, 2026, the Company issued a press release announcing the departure of Mr. Eno as the Company’s Chief Executive Officer, a member of the Board and principal executive officer. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    The information contained in this Item 8.01, including the related information set forth in the press release attached hereto as Exhibit 99.1, is being “furnished” and shall not be deemed “filed” with the Securities and Exchange Commission for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in such a filing.

     

    - 1 -

     

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    99.1   Press Release of HeartBeam, Inc. issued on June 24, 2026 (furnished herewith)
    104   Cover Page Interactive Data File (formatted as inline XBRL)

     

    - 2 -

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

     

      HeartBeam, Inc.
         
    Date: June 24, 2026 By: /s/ Branislav Vajdic
      Name:  Branislav Vajdic
      Title: President

     

    - 3 -

     

    Get the next $BEAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BEAT

    DatePrice TargetRatingAnalyst
    4/20/2026Buy → Hold
    D. Boral Capital
    3/31/2026$4.00Buy
    B. Riley Securities
    3/27/2026$5.00Buy
    D. Boral Capital
    3/16/2026$8.00Buy → Speculative Buy
    The Benchmark Company
    12/11/2025$8.00Speculative Buy → Buy
    The Benchmark Company
    12/8/2025$2.50Buy
    H.C. Wainwright
    10/31/2025$4.00Buy
    Roth Capital
    12/20/2021$9.00Speculative Buy
    Benchmark
    More analyst ratings

    $BEAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Ferrari Richard bought $46,000 worth of shares (57,500 units at $0.80), increasing direct ownership by 25% to 286,636 units (SEC Form 4)

    4/A - HeartBeam, Inc. (0001779372) (Issuer)

    4/24/26 4:05:03 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Cruickshank Tim

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    4/16/26 8:48:21 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Elfrink Willem

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    4/16/26 8:48:07 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    SEC Filings

    View All

    SEC Form DEFA14A filed by Heartbeam Inc.

    DEFA14A - HeartBeam, Inc. (0001779372) (Filer)

    6/25/26 8:30:01 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Heartbeam Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - HeartBeam, Inc. (0001779372) (Filer)

    6/24/26 5:28:27 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Heartbeam Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - HeartBeam, Inc. (0001779372) (Filer)

    6/22/26 4:15:22 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $BEAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    HeartBeam downgraded by D. Boral Capital

    D. Boral Capital downgraded HeartBeam from Buy to Hold

    4/20/26 8:06:13 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    B. Riley Securities initiated coverage on HeartBeam with a new price target

    B. Riley Securities initiated coverage of HeartBeam with a rating of Buy and set a new price target of $4.00

    3/31/26 8:12:24 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    D. Boral Capital initiated coverage on HeartBeam with a new price target

    D. Boral Capital initiated coverage of HeartBeam with a rating of Buy and set a new price target of $5.00

    3/27/26 8:50:13 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Amendment: Director Ferrari Richard bought $46,000 worth of shares (57,500 units at $0.80), increasing direct ownership by 25% to 286,636 units (SEC Form 4)

    4/A - HeartBeam, Inc. (0001779372) (Issuer)

    4/24/26 4:05:03 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    Director Ferrari Richard bought $50,000 worth of shares (29,412 units at $1.70), increasing direct ownership by 20% to 179,136 units (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    2/21/25 8:00:22 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    CFO Cruickshank Tim bought $30,000 worth of shares (17,647 units at $1.70) (SEC Form 4)

    4 - HeartBeam, Inc. (0001779372) (Issuer)

    2/21/25 7:55:14 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition

    Company will license its 3D ECG signal technology to established partners, moving beyond direct medical device sales Advancing toward heart attack detection as a key expansion of the platform Tailoring its technology to fit each market, while operating with a leaner, more focused structure Company to provide more details on strategy as part of Second Quarter 2026 conference call in August HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a reorganization to prioritize global market reach and capital efficiency while accelerating execution. The company has aligned its operation

    6/24/26 4:05:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Announces New Peer-Reviewed Article Demonstrating Potential to Help Identify Heart Attack Risk at Home

    Publication in JACC: Advances demonstrates that an algorithm combining the HeartBeam ECG device with patient risk factors and symptoms can accurately identify heart attack risk Study advances the scientific foundation supporting HeartBeam's planned indication expansion into heart attack detection Large market potential with over 20 million patients in the U.S. at risk of a heart attack HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a peer-reviewed article in JACC: Advances, a journal of the American College of Cardiology, demonstrating that a risk prediction algorithm incorpor

    6/2/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Reports First Quarter 2026 Results

    Signed First Commercial Partners in Leading Concierge Practices ClearCardio™ and Atelier Health Established Flagship Commercial Sites Across New York, Dallas, South Florida and Southern California Strategic Collaboration with Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms, Starting with Heart Attack Detection Strengthened Balance Sheet with $11.5 Million Public Offering Including Full Exercise of Over-Allotment Option Initiated Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Initiated Pilot Study of First On-Demand 12-Lead ECG Patch to Detect Ischemia Outside the Clinic Management to Host Webcast and Conference Call Today

    5/13/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Financials

    Live finance-specific insights

    View All

    HeartBeam Announces Strategic Shift to Accelerate Global Adoption of its Ambulatory ECG Signal Platform and Leadership Transition

    Company will license its 3D ECG signal technology to established partners, moving beyond direct medical device sales Advancing toward heart attack detection as a key expansion of the platform Tailoring its technology to fit each market, while operating with a leaner, more focused structure Company to provide more details on strategy as part of Second Quarter 2026 conference call in August HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a reorganization to prioritize global market reach and capital efficiency while accelerating execution. The company has aligned its operation

    6/24/26 4:05:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam to Host First Quarter 2026 Results Conference Call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern Time

    HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Wednesday, May 13, 2026 at 4:30 p.m. Eastern time to discuss its results for the first quarter ended March 31, 2026, and will be providing updates on key strategic growth initiatives, including its limited commercial launch for arrhythmia assessment, and developments on its extended-wear patch, heart attack detection and AI initiatives. A press release detailing these results will be issued prior to the call. HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will host the conference call, followed by a question-and-answe

    4/30/26 8:31:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Reports Fourth Quarter and Full Year 2025 Results

    HeartBeam Enters New Growth Phase Following FDA Clearance for First-Ever, Cable-Free Synthesized 12-Lead ECG for At-Home Arrhythmia Assessment First Commercial Partner ClearCardio™ to Bring HeartBeam's 3D ECG Technology to High-Growth Preventive Cardiology Market First Patients Enrolled in Heart Attack Detection Pilot Study, A Key Step Toward Future FDA Indication Expansion Completed the First Working Prototype of an Extended-Wear 12-Lead ECG Patch Strategic Collaboration with the Icahn School of Medicine at Mount Sinai to Accelerate Next-Generation AI-ECG Algorithms Management to Host Webcast and Conference Call Today at 4:30 p.m. ET   HeartBeam, Inc. (NASDAQ:BEAT), a

    3/12/26 4:01:00 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Leadership Updates

    Live Leadership Updates

    View All

    HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer

    Brings more than 25 years of experience in building and scaling groundbreaking cardiovascular technologies Will initially focus on launching the Company's FDA-cleared 12-lead ECG system for arrhythmia assessment Will lead the Company's broader commercialization strategy across key growth initiatives, including heart attack detection and the 12-lead ECG extended-wear patch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strate

    1/22/26 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth

    Board expansion reflects Company's commitment to leadership and innovation in remote cardiac monitoring HeartBeam, Inc., (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced the appointment of Chief Executive Officer, Robert Eno, to its Board of Directors. As the Company continues to make significant advancements towards commercial readiness, the Board elected to expand from eight to nine members to accommodate this addition. Mr. Eno joined HeartBeam as President in January 2023 and was appointed CEO in October 2024. With over 30 years of experience in the medical technology industry, he has a proven

    5/5/25 7:00:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    HeartBeam Announces FDA Clearance for At-Home, High-Fidelity Heart Monitoring Technology

    First cable-free, ambulatory ECG that captures the heart's electrical signals from three distinct directions for high-fidelity data collection and advanced diagnostics Patients can have the credit card-sized device with them at all times, ready to record an ECG whenever they feel symptoms and reduce delays in care Company to initiate Early Access Program to gain important patient and physician feedback on the use of the system in preparation for commercial launch HeartBeam, Inc. (NASDAQ:BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the US Food and Drug Administration (FDA) has granted 510(k) cl

    12/16/24 8:31:00 AM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    $BEAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    10/25/23 4:01:55 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    8/28/23 4:26:34 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D filed by Heartbeam Inc.

    SC 13D - HeartBeam, Inc. (0001779372) (Subject)

    6/2/23 2:36:13 PM ET
    $BEAT
    Medical/Dental Instruments
    Health Care